Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Rayzebio Inc. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 3 distinct examiners across 2 distinct art units. This distribution indicates that while the company's technology is concentrated within a few specialized groups, it is being reviewed by several different individuals.
MOSHER, ERIC PARKER is the busiest examiner for the company, currently holding 1 pending office action. Since there are multiple distinct examiners for the pending actions, each examiner is managing a single case. This lack of examiner concentration means that the company must adapt its prosecution tactics to the specific preferences and habits of the different USPTO professionals involved.
The use of 2 distinct art units for the pending office actions indicates some concentration within the USPTO's organizational structure. However, the presence of multiple examiners means the company must still navigate different individual examination styles. Successfully managing the pending matters will require a flexible approach that accounts for the nuances of both the art units and the individual examiners involved.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOSHER, ERIC PARKER | 1 | 100.0% | +0.0% |
| DONOHUE, SEAN R | 1 | 41.4% | +21.0% |
| MEJIAS, SAMANTHA LEE | 1 | 46.7% | +40.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18434621 | CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR PROTEINS | MOSHER, ERIC PARKER | — |
| 18431646 | CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR KRAS G12C PROTEINS | MEJIAS, SAMANTHA LEE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18431656 | CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR PROTEINS | DONOHUE, SEAN R | — |
| 18431646 | CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR KRAS G12C PROTEINS | MEJIAS, SAMANTHA LEE | — |
| Art Unit | Apps |
|---|---|
| 1618 | 2 |
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18434621 | CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR PROTEINS | MOSHER, ERIC PARKER | 1612 | §101§102§103§112DP | Non-Final OA | — | Pending | Feb 06, 2024 |
| 18431656 | CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR PROTEINS | DONOHUE, SEAN R | 1618 | §102§103DP | Non-Final OA | — | Pending | Feb 02, 2024 |
| 18431646 | CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR KRAS G12C PROTEINS | MEJIAS, SAMANTHA LEE | 1618 | §103§112 | Non-Final OA | — | Pending | Feb 02, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRayzebio Inc. has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Eric Parker Mosher has the most, with 1 of Rayzebio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
